Patent ID: 7279469

Claim:
A compound of formula II or II′: or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen; R 2 is Ar 1 , wherein Ar 1 is a phenyl group substituted with x independent occurrences of Q-R X , wherein x is 1-5; Q is a bond or is a C 1 -C 6 alkylidene chain wherein up to two methylene units of Q are optionally replaced by —NR—, —S—, —O—, —CS—, —CO 2 —, —OCO—, —CO—, —COCO—, —CONR—, —NRCO—, —NRCO 2 —, —SO 2 NR—, —NRSO 2 —, —CONRNR—, —NRCONR—, —OCONR—, —NRNR—, —NRSO 2 NR—, —SO—, —SO 2 —, —PO—, —PO 2 —, or —POR—; and each occurrence of R x is independently R′, halogen, NO 2 , CN, OR′, SR′, N(R′) 2 , NR′COR′, NR′CONR′ 2 , NR′CO 2 R′, COR′, CO 2 R′, OCOR′, CON(R′) 2 , OCON(R′) 2 , SOR′, SO 2 R′, SO 2 N(R′) 2 , NR′SO 2 R′, NR′SO 2 N(R′) 2 , COCOR′, or COCH 2 COR′, wherein at least one Q-R X is not hydrogen; R 3 is Ar 2 , wherein Ar 2 is an optionally substituted aryl group selected from pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thiophenyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, or an 8-12 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein said aryl group is optionally substituted with y occurrences of Z-R Y ; wherein y is 0-5, Z is a bond or is a C 1 -C 6 alkylidene chain wherein up to two methylene units of Z are optionally replaced by —NR—, —S—, —O—, —CS—, —CO 2 —, —OCO—, —CO—, —COCO—, —CONR—, —NRCO—, —NRCO 2 —, —SO 2 NR—, —NRSO 2 —, —CONRNR—, —NRCONR—, —OCONR—, —NRNR—, —NRSO 2 NR—, —SO—, or —SO 2 —; and each occurrence of R Y is independently R′, halogen, NO 2 , CN, OR′, SR′, N(R′) 2 , NR′COR′, NR′CONR′ 2 , NR′CO 2 R′, COR′, CO 2 R′, OCOR′, CON(R′) 2 , OCON(R′) 2 , SOR′, SO 2 R′, SO 2 N(R′) 2 , NR′SO 2 R′, NR′SO 2 N(R′) 2 , COCOR′, or COCH 2 COR′; and each occurrence of R is independently hydrogen or an optionally substituted C 1-6 aliphatic group; and each occurrence of R′ is independently hydrogen or an optionally substituted group selected from a C 1-6 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R and R′, two occurrences of R, or two occurrences of R′, are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; provided that: a) when R 3 is pyridyl, pyrimidinedione, then R 2 is not phenyl simultaneously substituted with one occurrence of OMe in the meta position, and one occurrence of oxazole in the para position; or b) when R 3 is unsubstituted pyrimidinyl, then R 2 is not p-OMe substituted phenyl, p-OEt substituted phenyl, or o-OMe substituted phenyl.